

SERIAL NO: 08/093,972

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jonathan W. Nyce : Art Unit: 1635  
Serial No.: 09/093,972 : Examiner: Dr. Epps  
Filed: June 9, 1998 : Appl. Ref. No.: EPI-00672  
For: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION &  
TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH  
BRONCHOCONSTRICTION, ALLERGY(IES) & INFLAMMATION

# 25/D

(NE)

Bill

4-13-01

SUPPLEMENTAL AMENDMENT

I hereby certify that this correspondence is being faxed at 703-305-7939, to the Assistant Commissioner for Patents, Washington DC 20231 on March 28, 2001, by Vivian Amzel.

SIGNATURE

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir/Madam:

Supplemental to the response to the Office Action of November 7, 2000, filed February 6, 2001, please amend the above identified patent application as follows.

IN THE SPECIFICATION

Please amend the specification as follows.

Page 11, after line 3, delete the following previously inserted paragraph:

"The method of the present invention may be used to treat airway disease in a subject for any reason, with the intention that adenosine content of antisense compounds be eliminated or reduced so as to prevent its liberation upon antisense degradation. Examples of airway diseases that may be treated by the method of the present invention include cystic fibrosis, asthma, chronic obstructive pulmonary disease, bronchitis, and other airway diseases characterized by an inflammatory response. Antisense nucleotides to the A<sub>1</sub> and A<sub>3</sub> receptors are shown to be effective in the downregulation of A<sub>1</sub> or A<sub>3</sub> in the cell. One novel feature of this treatment, as compared to traditional treatments for adenosine-mediated bronchoconstriction, is that administration is direct to the lungs. Additionally, a receptor protein itself is reduced in amount, rather than merely interacting with a drug, and toxicity is reduced. Other proteins that may be targeted with antisense